ReForm Biologics Announces An Evaluation Agreement for Enhancing Formulation of Two Clinical-stage Pipeline Programs

WOBURN, Mass.–(BUSINESS WIRE)–ReForm
Biologics, a pharmaceutical technology company developing innovative
biologic formulations to improve drug delivery and manufacturing, today
announced a new customer. ReForm will perform feasibility studies for
Bayer AG utilizing its innovative biotherapeutic technologies.

Reform’s viscosity-reducing excipients are applied to high concentration
biologic formulations to enable subcutaneous injection or
device-assisted administration, or to improve filtration unit
operations. Surfactant-replacing excipients are utilized to avoid the
degradation problems that accompany known surfactants for biological
formulations.

The work will be performed at ReForm Biologics’ facilities in Woburn,
Massachusetts.

About ReForm Biologics

ReForm Biologics has developed a technology platform that transforms the
formulation of biotherapeutics for the ultimate benefit of patients. Our
patented technology can enable alternative dosing, and improve
manufacturing efficiency for our biopharmaceutical partners and extend
product life-cycles. With multiple industry alliances to date, we offer
formulation development collaborations and product-specific licenses for
a broad spectrum of protein-based therapeutics.

We don’t make biologics — we make biologics better. www.reformbiologics.com

Contacts

Rob Kloppenburg
Shoreline Biotech Communications
(617) 930-5595